Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01726738
Title	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	UNC Lineberger Comprehensive Cancer Center
Indications	melanoma
Therapies	Dabrafenib + Trametinib
Age Groups:	adult
Covered Countries	USA